Longboard Pharmaceuticals, Inc.
| General Information | |
| Business: | We are a clinical-stage biopharmaceutical company focused on developing novel transformative medicines for neurological diseases. We were formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Our small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Our pipeline includes: *LP352, an oral centrally acting 5-hydroxytryptamine 2c receptor subtype (5-HT2c) super agonist, to treat developmental and epileptic encephalopathies (DEEs), including Dravet syndrome and Lennox-Gastaut syndome; this drug candidate is in a Phase 1 clinical trial, and we expect to initiate a Phase 1b/2a clinical trial in the first quarter of 2022; *LP143, a centrally active full cannabinoid Type 2 receptor (CB2) agonist in IND-enabling studies to treat neurodegenerative diseases associated with neuroinflammation caused by microglial activation, including amyotrophic lateral sclerosis (ALS), and *LP659, a centrally acting sphingosine-1 phosphate (S1P) receptor subtypes 1 and 5 (S1P1,5) modulator in IND-enabling studies for central nervous system (CNS) neuroinflammatory diseases. (IND stands for investigational new drug, a type of FDA application and authorization.) (Note: Longboard Pharmaceuticals priced its IPO on March 10, 2021: 5 million shares at $16 – the high end of its $14-to-$16 range – to raise $80 million.) |
| Industry: | Pharmaceuticals |
| Employees: | 6 |
| Founded: | 2020 |
| Contact Information | |
| Address | 6154 Nancy Ridge Drive San Diego, California 92121 |
| Phone Number | (619) 592-9775 |
| Web Address | http://www.longboardpharma.com/ |
| View Prospectus: | Longboard Pharmaceuticals, Inc. |
| Financial Information | |
| Market Cap | $253.8mil |
| Revenues | $0 mil (last 12 months) |
| Net Income | $-14.4 mil (last 12 months) |
| IPO Profile | |
| Symbol | LBPH |
| Exchange | NASDAQ |
| Shares (millions): | 5.0 |
| Price range | $16.00 - $16.00 |
| Est. $ Volume | $80.0 mil |
| Manager / Joint Managers | Citigroup/Evercore/Guggenheim Securities/Cantor Fitzgerald |
| CO-Managers | - |
| Expected To Trade: | 3/12/2021 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |